These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 25569737

  • 1. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
    Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A.
    Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737
    [Abstract] [Full Text] [Related]

  • 2. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
    Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S, ABIRISK consortium.
    Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539
    [Abstract] [Full Text] [Related]

  • 3. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S.
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [Abstract] [Full Text] [Related]

  • 4. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Hofmekler T, Bertha M, McCracken C, Martineau B, McKinnon E, Schoen BT, McElhanon BO, Tenjarla G, Kugathasan S, Sauer CG.
    J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
    [Abstract] [Full Text] [Related]

  • 5. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S.
    Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
    [Abstract] [Full Text] [Related]

  • 6. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.
    Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.
    Raffáč Š, Gombošová L, Gabzdilová J, Novotná L, Šajtyová K, Pekárová T, Kopolovets I, Tóth Š.
    Neuro Endocrinol Lett; 2017 Nov; 38(Suppl1):5-9. PubMed ID: 29200248
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A, Straathof JW, Derijks LJ.
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [Abstract] [Full Text] [Related]

  • 12. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B.
    Aliment Pharmacol Ther; 2018 Jan; 47(2):212-218. PubMed ID: 29124774
    [Abstract] [Full Text] [Related]

  • 13. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D'Haens GR, Kindermann A.
    Scand J Gastroenterol; 2015 Jan; 50(9):1110-7. PubMed ID: 25865965
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
    Imaeda H, Andoh A, Fujiyama Y.
    J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of infliximab: how to handle the problem?
    Baert F, De Vos M, Louis E, Vermeire S, Belgian IBD Research Group.
    Acta Gastroenterol Belg; 2007 Feb; 70(2):163-70. PubMed ID: 17715629
    [Abstract] [Full Text] [Related]

  • 18. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, Tripuraneni B, Rabizadeh S, Dubinsky MC.
    Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
    [Abstract] [Full Text] [Related]

  • 19. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Lega S, Phan BL, Rosenthal CJ, Gordon J, Haddad N, Pittman N, Benkov KJ, Dubinsky MC.
    Inflamm Bowel Dis; 2019 Jan 01; 25(1):134-141. PubMed ID: 29868777
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.